# Characterising protective immune responses to SARS-CoV-2 in urban and rural Malawi between February 2021 and April 2022

**Authors:** Mhairi J. McCormack, Louis Banda, Stephen Kasenda, Ellen C. Hughes, Lina Leonhard, Annie Mwale, Estelle McLean, Alison Price, Amelia Crampin, David Chaima, Abena S. Amoah, Tonney S. Nyirenda, Antonia Ho, Brian J. Willett

PMC · DOI: 10.1038/s41598-025-22599-7 · Scientific Reports · 2025-10-29

## TL;DR

This study examines immune responses to SARS-CoV-2 in urban and rural Malawi, finding that vaccination and prior infection boost immunity, but children and HIV-positive individuals have weaker protection.

## Contribution

The study provides longitudinal data on neutralising antibody responses in Malawi, comparing urban and rural populations and highlighting vulnerable groups.

## Key findings

- Neutralising antibody prevalence was higher in urban Lilongwe than rural Karonga.
- Hybrid immunity (infection plus vaccination) resulted in higher antibody titres than infection alone.
- Children under 15 and HIV-positive individuals had lower neutralising antibody responses.

## Abstract

SARS-CoV-2 transmission in Malawi remains unclear due to high proportions of mild/asymptomatic infections and limited diagnostics. Existing seroprevalence studies in Malawi have primarily used convenience samples and enzyme-linked immunosorbent assays (ELISAs). We assessed SARS-CoV-2 neutralisation in a longitudinal Malawian population-based cohort, assessing protective immunity post-infection and vaccination. Sera were obtained from rural (Karonga, n = 958) and urban (Lilongwe, n = 918) based participants at three-monthly intervals (February 2021-April 2022). Neutralising antibodies against SARS-CoV-2 were measured using human immunodeficiency (HIV)-based pseudotype assays in HIV-uninfected participants, and vesicular stomatitis virus-based assays in HIV-infected participants and an HIV-uninfected subset. Nucleocapsid ELISAs identified vaccinated participants also infected. SARS-CoV-2 neutralisation profiles increased in complexity over time from rising vaccination coverage and emerging variants. Neutralising antibody prevalence was higher in Lilongwe than Karonga (68.1% (CI 63.5–72.4) vs. 45.4% (CI 41.6–49.3), Survey 4). Hybrid immune and solely vaccinated participants exhibited higher titres than those solely infected. Children < 15 years had the lowest neutralising antibody titres among infected (not vaccinated) participants. People living with HIV had lower neutralising responses than those HIV-uninfected, particularly post vaccination. We therefore recommend surveillance of children and people living with HIV as low neutralisation responses increase reinfection risk. COVID-19 vaccination should be prioritised for HIV-infected individuals.

The online version contains supplementary material available at 10.1038/s41598-025-22599-7.

## Linked entities

- **Diseases:** SARS-CoV-2 (MONDO:0100096), COVID-19 (MONDO:0100096)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Diseases:** HIV (MESH:D015658), infected (MESH:D007239), COVID-19 (MESH:D000086382)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606], Vesicular stomatitis virus (species) [taxon 11276], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12572322/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12572322/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12572322/full.md

---
Source: https://tomesphere.com/paper/PMC12572322